IMDPharm

IMDPharm is a South Korean biotechnology company specializing in the development of innovative drug delivery systems (DDS) to enhance the efficacy and safety of existing therapeutics. The company focuses on respiratory diseases, oncology, and metabolic disorders, utilizing its proprietary platform to create optimized formulations for inhalation and oral delivery. Their lead programs include advanced treatments for chronic obstructive pulmonary disease (COPD) and asthma, as well as novel approaches for hair loss and liver diseases. By leveraging drug repositioning and formulation technology, IMDPharm aims to reduce development risks and provide improved clinical outcomes for patients with high unmet medical needs.